Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

1(14%)

Results Posted

40%(2 trials)

Terminated

1(14%)

Phase Distribution

Ph early_phase_1

14%

Ph not_applicable

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

1(16.7%)

N/ANon-phased studies

5(83.3%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Terminated(1)

Detailed Status

Completed5

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (16.7%)

N/A5 (83.3%)

Trials by Status

completed571%

recruiting114%

terminated114%

Recent Activity

1 active trials

Showing 5 of 7

recruitingnot_applicable

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

NCT06295757

completed

Clinical Trials (7)

Showing 7 of 7 trials

NCT06295757Not Applicable

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

Recruiting

NCT03863509

E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease

Completed

NCT01867242Not Applicable

Methods Project 4: Clinical Trial

Completed

NCT03111537Not Applicable

Methods Project 4: Clinical Trial - Amended

Completed

NCT02612701Not Applicable

E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion

Terminated

NCT00644137Early Phase 1

GABA (Gamma Amino Butyric Acid) Medication for Tobacco

Completed

NCT04255459Not Applicable

Post-Market Surveillance of Tobacco Products

Completed

All 7 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 7